HHT is not a TGFβ disease

Blood

Volumn 111, Issue 2, 2008, Pages 478-

  Bailly, Sabine ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN RECEPTOR 1; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 9; BONE MORPHOGENETIC PROTEIN RECEPTOR 1B; TRANSFORMING GROWTH FACTOR BETA;

DISEASE COURSE; ENDOTHELIUM CELL; GENE; GENE DELETION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PULMONARY HYPERTENSION; RENDU OSLER WEBER DISEASE; SHORT SURVEY; TRANSFORMING GROWTH FACTOR BETA GENE; TRANSGENIC MOUSE; VASCULAR ENDOTHELIUM;

EID: 38349169020     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-10-118042     Document Type: Short Survey

References (4)

1. Goumans MJ, Valdimarsdottir G, Itoh S, Rosendahl A, Sideras P, ten Dijke P. Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. EMBO J. 2002;21:1743-1753.
2. Seki T, Hong KH, Oh SP. Nonoverlapping expression patterns of ALK1 and ALK5 reveal distinct roles of each receptor in vascular development. Lab Invest. 2006;86:116-129.
3. David L, Mallet C, Mazerbourg S, Feige JJ, Bailly S. Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells. Blood. 2007;109:1953-1961.
4. Liu D, Wang J, Kinzel B, et al. Dosage-dependent requirement of BMP type II receptor for maintenance of vascular integrity. Blood. 2007;110:1502-1510.